Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TIV-HA vaccine-Sanofi-influenza-respiratory syncytial virus infection-human metapneumovirus infection
- Development stage
- Unknown
- Lead developer
- Sanofi
- Modality
- Recombinant Proteins and Enzymes, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
This entry refers to a group of experimental vaccine formulations developed by Sanofi and evaluated in a Phase 1 clinical trial (NCT05306041). The program investigated different formulations of a trivalent influenza vaccine (TIV-HA) and a combined vaccine targeting respiratory syncytial virus (RSV), human metapneumovirus (hMPV), and parainfluenza virus type 3 (PIV3). The TIV-HA component targets the hemagglutinin (HA) proteins of three influenza strains, while the multivalent respiratory vaccine targets the fusion (F) proteins of RSV, hMPV, and PIV3. These candidates utilize lipid nanoparticle (LNP) delivery technology, which is characteristic of mRNA-based vaccine platforms, designed to elicit robust immune responses against multiple major respiratory pathogens. The trial aimed to assess the safety and immunogenicity of these next-generation formulations in healthy adults aged 18-49 years.
- Other names
- Multivalent Influenza and RSV/hMPV/PIV3 VaccinesSanofi Respiratory Vaccine Program
02
Targets
HMPV F (Human metapneumovirus fusion protein)HA (Hemagglutinin)RSV F (Respiratory syncytial virus fusion protein)HPIV-3 F (Human parainfluenza virus 3 fusion protein)
Beyond the preview
Go deeper on TIV-HA vaccine-Sanofi-influenza-respiratory syncytial virus infection-human metapneumovirus infection.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TIV-HA vaccine-Sanofi-influenza-respiratory syncytial virus infection-human metapneumovirus infection.